Division of Research, Kaiser Permanente Northern California, Oakland.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco.
JAMA Netw Open. 2022 Nov 1;5(11):e2244086. doi: 10.1001/jamanetworkopen.2022.44086.
Prenatal cannabis use is associated with health risks for mothers and their children. Prior research suggests that rates of prenatal cannabis use in Northern California increased during the COVID-19 pandemic, but it is unknown whether increases varied with the local cannabis retail and policy environment.
To test whether pandemic-related increases in prenatal cannabis use were greater among pregnant individuals with greater retail availability of cannabis around their homes or among those living in jurisdictions that allowed storefront retailers.
DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional, population-based time series study used data from pregnancies in the Kaiser Permanente Northern California health care system screened for cannabis use before (January 1, 2019, to March 31, 2020) and during (April 1 to December 31, 2020) the early COVID-19 pandemic. Proximity to the nearest retailer and number of retailers within a 15-minute drive from one's home and local cannabis storefront retailer policy (banned vs permitted) were calculated. Interrupted time series models were fit using multiplicative and additive Poisson regression, adjusting for age and race and ethnicity.
The COVID-19 pandemic.
Prenatal cannabis use based on universal urine toxicology tests conducted during early pregnancy at entrance to prenatal care.
The sample (n = 99 127 pregnancies) included 26.2% Asian or Pacific Islander, 6.8% Black, 27.6% Hispanic, 34.4% non-Hispanic White, and 4.9% other, unknown, or multiracial individuals, with a mean (SD) age of 30.8 (5.3) years. Prenatal cannabis use before (6.8%) and during (8.2%) the pandemic was associated with closer proximity to a retailer, greater retailer density, and residing in a jurisdiction that permitted vs banned retailers. There was a greater absolute increase in cannabis use from before to during the pandemic among those within a 10-minute drive (<10 minutes: adjusted rate difference [aRD], 0.93 cases/100 patients; 95% CI, 0.56-1.29 cases/100 patients; ≥10 minutes: aRD, 0.40 cases/100 patients; 95% CI, 0.12-0.68 cases/100 patients; interaction P = .02). Otherwise, relative and absolute rates increased similarly across categories of cannabis retailer proximity/density and local policy (interaction P > .05).
Prenatal cannabis use was more common among individuals living in areas with greater retail availability of cannabis. Although relative rates increased similarly during the pandemic regardless of local cannabis retail and policy environment, there was a larger absolute increase associated with living closer to a storefront cannabis retailer. Continued monitoring of local cannabis policy, the retail environment, and prenatal cannabis use is needed.
产前大麻使用与母婴健康风险相关。先前的研究表明,北加利福尼亚州产前大麻使用的比例在 COVID-19 大流行期间有所增加,但尚不清楚这种增加是否因当地大麻零售和政策环境而异。
测试在家庭周围大麻零售可用性更高的孕妇或居住在允许店面零售商的司法管辖区中,与产前大麻使用相关的大流行期间增加是否更大。
设计、地点和参与者:这是一项基于人群的横断面时间序列研究,使用 Kaiser Permanente 北加利福尼亚医疗保健系统中筛查大麻使用情况的怀孕数据,这些数据在 COVID-19 大流行之前(2019 年 1 月 1 日至 2020 年 3 月 31 日)和期间(2020 年 4 月 1 日至 12 月 31 日)进行。计算了离最近零售商的距离和离家庭 15 分钟车程内的零售商数量,以及当地的大麻店面零售商政策(禁止与允许)。使用乘法和加法泊松回归拟合中断时间序列模型,调整年龄和种族和民族因素。
COVID-19 大流行。
根据产前护理初诊时进行的普遍尿液毒物学测试,确定产前大麻使用情况。
样本(n = 99127 例妊娠)包括 26.2%的亚洲或太平洋岛民、6.8%的黑人、27.6%的西班牙裔、34.4%的非西班牙裔白人,以及 4.9%的其他、未知或多种族裔个体,平均(SD)年龄为 30.8(5.3)岁。产前大麻使用在大流行前(6.8%)和大流行期间(8.2%)与更接近零售商、零售商密度更大以及居住在允许 vs 禁止零售商的司法管辖区相关。在 10 分钟车程内的人群中,从大流行前到大流行期间大麻使用的绝对增加更大(<10 分钟:调整后的率差异[aRD],0.93 例/100 例患者;95%CI,0.56-1.29 例/100 例患者;≥10 分钟:aRD,0.40 例/100 例患者;95%CI,0.12-0.68 例/100 例患者;交互 P = .02)。否则,相对和绝对比率在大麻零售商接近/密度和当地政策的各个类别中增加相似(交互 P > .05)。
产前大麻使用在零售可用性更高的地区更为普遍。尽管在大流行期间,无论当地大麻零售和政策环境如何,相对比率都相似增加,但与靠近店面大麻零售商的距离增加相关的绝对增加更大。需要继续监测当地的大麻政策、零售环境和产前大麻使用情况。